Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsPreferred Shares RepurchasedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Change in Account Payables (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Change in Account Payables for 17 consecutive years, with $178743.0 as the latest value for Q1 2026.

  • Quarterly Change in Account Payables rose 31.09% to $178743.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $628716.0 through Jan 2026, up 83728.8% year-over-year, with the annual reading at $9835.0 for FY2025, 96.23% down from the prior year.
  • Change in Account Payables for Q1 2026 was $178743.0 at PharmaCyte Biotech, down from $469711.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $589849.0 in Q3 2023, with the low at -$591967.0 in Q4 2023.
  • Average Change in Account Payables over 5 years is $46515.2, with a median of $112499.0 recorded in 2022.
  • Peak annual rise in Change in Account Payables hit 5525.14% in 2022, while the deepest fall reached 6606.06% in 2022.
  • Over 5 years, Change in Account Payables stood at $302251.0 in 2022, then tumbled by 295.85% to -$591967.0 in 2023, then surged by 65.31% to -$205357.0 in 2024, then surged by 328.73% to $469711.0 in 2025, then plummeted by 61.95% to $178743.0 in 2026.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $178743.0, $469711.0, and $66005.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.